Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Aug 17, 2021	YANCOPOULOS GEORGE Director, President and Chief Scientific Trans History: 617	Director, President and Chief Scientific	Form 4	Other acquisition or disposition	--	--	213,693
Jun 24, 2021	YANCOPOULOS GEORGE Director, President and Chief Scientific Trans History: 617	Director, President and Chief Scientific	Form 4	Bona fide gift	211,585	--	213,693
Jan 05, 2010	VAGELOS P ROY Director Trans History: 742	Director	Form 4	Bona fide gift	8,595	--	215,127
Dec 15, 2009	SCHLEIFER LEONARD S Director, CEO and President, Ten Percent Owner Trans History: 404	Director, CEO and President, Ten Percent Owner	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	66,138	$19.89	215,920
Dec 15, 2004	SCHLEIFER LEONARD S Director, Chief Exec Officer & President, Ten Percent Owner Trans History: 404	Director, Chief Exec Officer & President, Ten Percent Owner	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	218,389	--	218,389
Jan 31, 2007	VAGELOS P ROY Director Trans History: 742	Director	Form 4	Other acquisition or disposition	--	--	219,801
Dec 20, 2006	VAGELOS P ROY Director Trans History: 742	Director	Form 4	Other acquisition or disposition	--	--	219,801
Jun 20, 2006	VAGELOS P ROY Director Trans History: 742	Director	Form 4	Bona fide gift	219,801	--	219,801
Jun 14, 2006	VAGELOS P ROY Director Trans History: 742	Director	Form 4	Other acquisition or disposition (describe transaction)	63,511	--	221,291
Mar 05, 2013	SCHLEIFER LEONARD S Director, President & CEO Trans History: 404	Director, President & CEO	Form 4	Open market or private sale of non-derivative or derivative security	19,146	$175.21	222,941

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media